- Home
- FOXX vs CRVO Comparison
FOXX vs CRVO Comparison
Compare FOXX & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOXX | CRVO |
|---|---|---|
| Founded | 2017 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 35.9M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | FOXX | CRVO |
|---|---|---|
| Price | $4.11 | $3.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 6.9K | ★ 49.9K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,006,510.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.71 | $2.82 |
| 52 Week High | $8.70 | $13.13 |
Technical Indicators
Market Signals| Indicator | FOXX | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 34.33 | 36.43 |
| Support Level | $3.80 | N/A |
| Resistance Level | $4.83 | $4.27 |
| Average True Range (ATR) | 0.33 | 0.26 |
| MACD | -0.15 | -0.07 |
| Stochastic Oscillator | 14.30 | 28.77 |
Price Performance
Historical ComparisonAbout FOXX Foxx Development Holdings Inc.
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals. The company's current revenue stream is derived from the sales of tablets and smartphones.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.